CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Preferred Stock	Common Stock	Additional Paid-in Capital	Common Stock to be Issued	Accumulated Deficit	Total
Beginning balance at Dec. 31, 2021		$ 100	$ 218,762		$ (95,683)	$ 123,179
Beginning balance (in shares) at Dec. 31, 2021		99,976,253
Warrant exercise (in shares)						0
Issuance of Series A Convertible Preferred Stock, net of issuance costs	$ 9,273					$ 9,273
Issuance of Series A Convertible Preferred Stock, net of issuance costs (in shares)	9,566
Common stock offering, net of issuance costs		$ 5	33,930			33,935
Common stock offering, net of issuance costs (in shares)		4,992,946
Stock-based compensation expense			482			482
Preferred stock dividends	$ 284				(284)
Net loss					(31,852)	(31,852)
Ending balance at Jun. 30, 2022	$ 9,557	$ 105	253,174		(127,819)	135,017
Ending balance (in shares) at Jun. 30, 2022	9,566	104,969,199
Beginning balance at Mar. 31, 2022	$ 9,273	$ 101	225,545		(113,911)	121,008
Beginning balance (in shares) at Mar. 31, 2022	9,566	100,790,239
Common stock offering, net of issuance costs		$ 4	27,147			27,151
Common stock offering, net of issuance costs (in shares)		4,178,960
Stock-based compensation expense			482			482
Preferred stock dividends	$ 284				(239)	45
Net loss					(13,669)	(13,669)
Ending balance at Jun. 30, 2022	$ 9,557	$ 105	253,174		(127,819)	135,017
Ending balance (in shares) at Jun. 30, 2022	9,566	104,969,199
Beginning balance at Dec. 31, 2022	$ 9,273	$ 145	294,810		(186,474)	117,754
Beginning balance (in shares) at Dec. 31, 2022	9,566	145,492,971
Common stock reacquired and exchanged for warrants		$ (12)	(12,479)			(12,491)
Common stock reacquired and exchanged for warrants (in shares)		(12,000,000)
Warrant issuance in conjunction with debt modification			16,036			16,036
Warrant offerings			14,991			14,991
Warrant exercise		$ 26	3,487			$ 3,513
Warrant exercise (in shares)		25,647,821				1,130,403
Common stock offering, net of issuance costs		$ 44	32,304			$ 32,348
Common stock offering, net of issuance costs (in shares)		43,812,902
Convertible promissory notes converted to common stock		$ 12	4,693			4,705
Convertible promissory notes converted to common stock (in shares)		11,762,956
Stock-based compensation expense and issuance of stock		$ 1	2,610			2,611
Stock-based compensation expense and issuance of stock (in shares)		1,839,731
Tax withholdings related to net share settlements of stock based compensation awards			(852)			$ (852)
Tax withholdings related to net share settlements of stock-based compensation awards (in shares)		(500,494)				(500,494)
Net loss					(43,797)	$ (43,797)
Ending balance at Jun. 30, 2023	$ 9,273	$ 216	355,600		(230,271)	134,818
Ending balance (in shares) at Jun. 30, 2023	9,566	216,055,887
Beginning balance at Mar. 31, 2023	$ 9,273	$ 186	345,195	$ 4,390	(212,731)	146,313
Beginning balance (in shares) at Mar. 31, 2023	9,566	186,268,682
Warrant exercise		$ 26	3,487			3,513
Warrant exercise (in shares)		25,647,821
Common stock offering, net of issuance costs		$ 3	6,036			6,039
Common stock offering, net of issuance costs (in shares)		3,048,196
Common stock to be issued, net of issuance costs				$ (4,390)		(4,390)
Stock-based compensation expense and issuance of stock		$ 1	1,734			1,735
Stock-based compensation expense and issuance of stock (in shares)		1,591,682
Tax withholdings related to net share settlements of stock based compensation awards			(852)			(852)
Tax withholdings related to net share settlements of stock-based compensation awards (in shares)		(500,494)
Net loss					(17,540)	(17,540)
Ending balance at Jun. 30, 2023	$ 9,273	$ 216	$ 355,600		$ (230,271)	$ 134,818
Ending balance (in shares) at Jun. 30, 2023	9,566	216,055,887